ozureprubart (RPT904) / Jemincare, RAPT Therap - LARVOL DELTA

In October, completed an underwritten public offering of 8,333,334 shares of common stock at a price of $30.00 per share for gross proceeds of $250 million. The Company’s current cash balance is projected to fund operations to mid-2028, which includes the planned initiation of Phase 3 studies of ozureprubart in CSU. (RAPT Therapeutics Press Release)

Financing • Chronic Spontaneous Urticaria

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: RAPT Therapeutics, Inc.

Monotherapy • New P2 trial • Allergy • Food Hypersensitivity • Immunology

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria (GlobeNewswire) - "The data from both the RPT904 Q8W and Q12W treatment arms showed numerically greater improvements on the UAS7 endpoint and numerically higher proportion of patients with UAS7=0 at all timepoints (Weeks 8, 12 and 16) compared to omalizumab Q4W...The mean baseline UAS7 scores (±SD) in the RPT904 Q8W, Q12W and omalizumab Q4W arms were 28.7 (±7.2), 28.9 (±6.6) and 28.8 (±7.9), respectively...RPT904 was well tolerated with no serious adverse events related to study drug and no treatment-related adverse events resulting in treatment discontinuation....'Based on these positive results, we are preparing to advance JYB1904 to Phase 3.'"

New P3 trial • P2 data • Chronic Spontaneous Urticaria

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies (GlobeNewswire) - "The study will involve approximately 30 sites in the U.S., Canada and Australia....The prestIgE Phase 2b trial is designed to assess the efficacy and safety of ozureprubart monotherapy in participants with IgE-mediated food allergy."

Trial status • Allergy

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) (GlobeNewswire) - "RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET."

P2 data • Chronic Spontaneous Urticaria

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy (The Manila Times) - "The planned Phase 2b trial in food allergy is a randomized double-blind placebo-controlled study designed to evaluate the safety and efficacy of RPT904 dosed every 8 weeks (Q8W) and every 12 weeks (Q12W)...'We are on track to initiate our Phase 2b clinical trial by the end of the year'..."

IND • Allergy

safety, pharmacokinetics, pharmacodynamics effects and immunogenicity of jyb194, a novel half-life extended anti-ige monoclonal antibody: a randomized, double-blind, placebo and positive controlled study in heathy participants (EADV 2025) - "JYB1904 was well tolerated. No additional significant safety risks were observed compared with omalizumab. JYB1904 exhibited favorable PK/PD characteristics supporting longer treatment interval, such as every 8 or 12 weeks, for further clinical studies."

Clinical • PK/PD data • Asthma • Dermatology • Food Hypersensitivity • Immunology • Inflammation • Respiratory Diseases • Urticaria

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of a Single-Dose JYB1904 in Healthy Chinese Participants: A Phase Ia, Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, Clin Transl Sci) - "PD results showed significant free IgE suppression, with JYB1904 demonstrating stronger activity than omalizumab at equivalent doses. JYB1904 offers promising clinical advantages over omalizumab, including extended dosing intervals and enhanced efficacy, warranting further investigation for allergic asthma treatment."

Clinical • Journal • PK/PD data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Trial of JYB1904 in Patients With Allergic Asthma (clinicaltrials.gov) - P2 | N=69 | Active, not recruiting | Sponsor: Jemincare | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

RAPT Therapeutics Reports First Quarter 2025 Financial Results (RAPT Therapeutics Press Release) - "Research and development expenses for the first quarter of 2025 were $12.0 million, compared to $24.8 million for the same period in 2024. The decrease in research and development expenses was primarily due to decreases in costs related to development of zelnecirnon and tivumecirnon, personnel, lab supplies, non-cash stock-based compensation and facilities, partially offset by increases in costs related to development of RPT904 and early-stage programs."

Commercial • Immunology

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) - "'We expect to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025 and await clinical data later this year from our partner Jemincare to guide our development strategy in CSU.'"

New P2b trial • P2 data • Allergy • Chronic Spontaneous Urticaria • Immunology

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody (GlobeNewswire) - "RAPT Therapeutics, Inc...and Shanghai Jemincare Pharmaceutical Co., Ltd...today announced they have entered into an exclusive license agreement for JYB1904 (RAPT designation RPT904), a clinical-stage, half-life extended anti-immunoglobulin E (IgE) monoclonal antibody. Under the terms of the license agreement, RAPT is granted worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan...to develop and commercialize RPT904. As consideration for the license, Jemincare receives a $35 million upfront license fee, up to $672.5 million in additional payments upon the achievement of various regulatory and commercial milestones, and royalties on future sales of RPT904 outside the Jemincare Territory...Jemincare expects to have topline data from the Phase 2 asthma trial in the second half of 2025. The Phase 2 trial in CSU is focused on evaluating safety and efficacy, and Jemincare expects to have topline data from this trial in the first half of 2026."

Licensing / partnership • P2 data • Asthma • Chronic Spontaneous Urticaria • Immunology • Urticaria

Trial of JYB1904 in Chronic Spontaneous Urticaria. (clinicaltrials.gov) - P2 | N=135 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Trial of JYB1904 in Chronic Spontaneous Urticaria. (clinicaltrials.gov) - P2 | N=135 | Not yet recruiting | Sponsor: Jemincare

New P2 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Trial of JYB1904 in Allergic Asthma (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Trial of JYB1904 in Allergic Asthma (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Jemincare

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Jemincare | Active, not recruiting ➔ Completed

Trial completion

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Jemincare | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Jemincare

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases